72209-27-9 Usage
Uses
Used in Pharmaceutical Industry:
(2S,3S,4R,5R)-N-ethyl-3,4-dihydroxy-5-(1-hydroxy-6-imino-purin-9-yl)oxolane-2-carboxamide is used as a potential therapeutic agent for various applications due to its structural resemblance to purine-based molecules. Its interaction with purine receptors and involvement in cellular signaling pathways may offer novel treatment options for diseases related to these mechanisms.
Used in Research and Development:
In the field of scientific research, (2S,3S,4R,5R)-N-ethyl-3,4-dihydroxy-5-(1-hydroxy-6-imino-purin-9-yl)oxolane-2-carboxamide serves as a valuable compound for studying the role of purine derivatives in biological systems. Its unique structure and properties make it a promising candidate for investigating the mechanisms of purine receptor interactions and their implications in cellular processes.
Used in Drug Design and Discovery:
(2S,3S,4R,5R)-N-ethyl-3,4-dihydroxy-5-(1-hydroxy-6-imino-purin-9-yl)oxolane-2-carboxamide is utilized in drug design and discovery efforts to identify new lead compounds with potential therapeutic benefits. Its structural features and biological activities provide a foundation for the development of innovative drugs targeting purine-related pathways and receptors.
Check Digit Verification of cas no
The CAS Registry Mumber 72209-27-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,2,2,0 and 9 respectively; the second part has 2 digits, 2 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 72209-27:
(7*7)+(6*2)+(5*2)+(4*0)+(3*9)+(2*2)+(1*7)=109
109 % 10 = 9
So 72209-27-9 is a valid CAS Registry Number.
InChI:InChI=1/C12H16N6O5/c1-2-14-11(21)8-6(19)7(20)12(23-8)17-3-15-5-9(13)18(22)4-16-10(5)17/h3-4,6-8,12-13,19-20,22H,2H2,1H3,(H,14,21)/b13-9-/t6-,7+,8-,12+/m0/s1
72209-27-9Relevant academic research and scientific papers
Costanzi,Lambertucci,Portino,Volpini,Vittori,Cristalli
, p. 415 - 418 (2005)
In an attempt to improve the A2A selectivity of the 2-(aryl)alkylthio derivatives of adenosine, we planned the synthesis of the corresponding derivatives of the 5′-N-ethylcarboxamidoadenosine (NECA). For this purpose, we designed the synthesis of 2-mercapto-NECA to be pursued by means of an opening-closure method. We obtained the open AICAR analog; however, ring closure efforts failed to give the desired compound. The newly synthesized AICAR derivative could potentially be endowed with antiviral or antitumoral activity. Copyright Taylor & Francis, Inc.
